TheraRadar

Celldex

Pre-Approval PRO BETA
40
Total Trials
5
Phase 3
15
Phase 2
8
Recruiting
279
Score

Pipeline by Phase

Phase 3
5
Phase 2
15
Phase 1
23

Therapeutic Focus

Chronic Spontaneous Urticaria Non-small Cell Lung Cancer Head and Neck Cancer Gastric Cancer Ovarian Cancer

Clinical Trials (40)

NCT07256392 Phase 3 RECRUITING

Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

Started: 11/25/2025

NCT07266402 Phase 3 RECRUITING

A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)

Started: 1/15/2026

NCT06455202 Phase 3 ACTIVE NOT RECRUITING

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

Started: 7/19/2024

NCT06445023 Phase 3 ACTIVE NOT RECRUITING

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

Started: 7/11/2024

NCT01480479 Phase 3 COMPLETED

Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

Started: 11/1/2011

NCT06727552 Phase 2 ACTIVE NOT RECRUITING

A Study of Barzolvolimab in Patients With Atopic Dermatitis

Started: 12/18/2024

NCT06366750 Phase 2 ACTIVE NOT RECRUITING

A Study of Barzolvolimab in Patients With Prurigo Nodularis

Started: 4/12/2024

NCT05774184 Phase 2 COMPLETED

A Study of CDX-0159 in Patients With Eosinophilic Esophagitis

Started: 6/1/2023

NCT05405660 Phase 2 COMPLETED

A Study of CDX-0159 in Patients With Chronic Inducible Urticaria

Started: 6/28/2022

NCT05368285 Phase 2 COMPLETED

A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Started: 5/19/2022

NCT03254927 Phase 2 TERMINATED

A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Started: 3/27/2018

NCT01498328 Phase 2 COMPLETED

A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

Started: 12/1/2011

NCT01094496 Phase 2 TERMINATED

A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)

Started: 4/1/2010

NCT02302339 Phase 2 TERMINATED

A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma

Started: 11/1/2014

NCT01997333 Phase 2 COMPLETED

Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer

Started: 11/1/2013

NCT01156753 Phase 2 COMPLETED

A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer

Started: 7/1/2010

NCT02200380 Phase 2 TERMINATED

A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs

Started: 7/1/2014

NCT07330778 Phase 1 RECRUITING

A Study of CDX-622 in Participants With Mild to Moderate Asthma

Started: 2/1/2026

NCT06650761 Phase 1 ACTIVE NOT RECRUITING

A Phase I Study of CDX-622

Started: 11/1/2024

NCT05788484 Phase 1 COMPLETED

A Study of CDX-585 in Patients With Advanced Malignancies

Started: 5/11/2023

NCT03329950 Phase 1 COMPLETED

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Started: 12/1/2017

NCT04944862 Phase 1 COMPLETED

A Study of CDX-0159 in Patients With Prurigo Nodularis

Started: 11/8/2021

NCT04538794 Phase 1 COMPLETED

A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Started: 9/24/2020

NCT04440943 Phase 1 COMPLETED

A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies

Started: 8/4/2020

NCT04548869 Phase 1 COMPLETED

A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria

Started: 11/24/2020

NCT05031624 Phase 1 COMPLETED

A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects

Started: 8/30/2021

NCT04146129 Phase 1 COMPLETED

A Phase 1 Study of CDX-0159

Started: 10/29/2019

NCT02837991 Phase 1 TERMINATED

A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma

Started: 6/1/2016

NCT02335918 Phase 1 COMPLETED

A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

Started: 1/1/2015

NCT02473731 Phase 1 COMPLETED

A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients

Started: 10/1/2015

NCT02642016 Phase 1 COMPLETED

A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors

Started: 12/1/2015

NCT02386111 Phase 1 TERMINATED

A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma

Started: 5/1/2015

NCT02543645 Phase 1 TERMINATED

A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer

Started: 10/1/2015

NCT01460134 Phase 1 COMPLETED

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Started: 10/1/2011

NCT02456701 Phase 1 COMPLETED

Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379

Started: 6/1/2015

NCT02014909 Phase 1 COMPLETED

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors

Started: 1/1/2014

NCT01465139 Phase 1 COMPLETED

A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers

Started: 10/1/2011

NCT02413827 Phase 1 TERMINATED

A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma

Started: 4/1/2015

NCT00948961 Phase 1 COMPLETED

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Started: 9/1/2009

NCT01791686 Phase 1 TERMINATED

Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease

Started: 1/1/2013

Drug Candidates

CDX-622 barzolvolimab Barzolvolimab Matching placebo Matching Placebo Normal Saline CDX-585 CDX-1140 CDX-301 pembrolizumab
Activity Status: Active
Last Trial Started: 2/1/2026
Last Trial Ended: 1/23/2026
Trials (12 months): 3
Completed Trials: 23
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.